Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 3988-3993

  Deshpande, Abhishek ^a,b   Hurless, Kelly ^b   Cadnum, Jennifer L ^b   Chesnel, Laurent ^c   Gao, Lihong ^c   Chan, Luisa ^d   Kundrapu, Sirisha ^b   Polinkovsky, Alexander ^b   Donskey, Curtis J ^b,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Second Genome Inc   (United States)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; FIDAXOMICIN; METRONIDAZOLE; SODIUM CHLORIDE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTEROIDES; CLOSTRIDIUM; CLOSTRIDIUM LEPTUM; COLONY FORMING UNIT; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FECES ANALYSIS; FIRMICUTES; HUMAN; INTESTINE FLORA; LOW DRUG DOSE; MICROBIOME; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEOBACTERIA; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; BACTEROIDES INFECTIONS; DRUG EFFECTS; FECES; FEMALE; GENETICS; INTESTINE; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEROIDES INFECTIONS; BETA-LACTAMASES; CLOSTRIDIUM; FECES; FEMALE; FIRMICUTES; INTESTINES; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; REAL-TIME POLYMERASE CHAIN REACTION; VANCOMYCIN; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84977117452     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02590-15     Document Type: Article

References (16)

1. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
2. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55(Suppl 2):S132-S142. http://dx.doi.org/10.1093/cid/cis338.
3. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T. 2010. A new macrocycle antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156:3354-3359. http://dx.doi.org/10.1099/mic.0.042010-0.
4. Al-Nassir W, Sethi AK, Riggs MM, Li Y, Pultz MJ, Donskey CJ. 2008. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52:2403-2406. http://dx.doi.org/10.1128/AAC.00090-08.
5. Sethi AK, Al-Nassir W, Nerandzic MM, Donskey CJ. 2009. Skin and environmental contamination with vancomycin-resistant enterococci in patients being treated with oral metronidazole versus oral vancomycin for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 30:13-17. http://dx.doi.org/10.1086/592710.
6. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. 2012. Reduced acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 55(Suppl 2):S121-S126. http://dx.doi.org/10.1093/cid/cis440.
7. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. 2000. Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 18:1830-1833.
8. Hoyen CK, Pultz NJ, Paterson DL, Aron DC, Donskey CJ. 2003. Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 47:3610-3612. http://dx.doi.org/10.1128/AAC.47.11.3610-3612.2003.
9. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. CLSI document 32(3):M100-S20. CLSI, Wayne, PA.
10. Shue YK, Sears PS, Shangle S, Walsh RB, Lee C, Gorbach SL, Okumu F, Preston RA. 2008. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 52:1391-1395. http://dx.doi.org/10.1128/AAC.01045-07.
11. Gonzales M, Pepin J, Frost EH, Carrier JC, Sirard S, Fortier LC, Valiquette L. 2010. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 10:363. http://dx.doi.org/10.1186/1471-2334-10-363.
12. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. 1997. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 25:729-732. http://dx.doi.org/10.1086/513755.
13. Zapala MA, Schork NJ. 2006. Multivariate regression analysis of distance matrices for testing associations between gene expression patterns and related variables. Proc Natl Acad Sci U S A 103:19430-19435. http://dx.doi.org/10.1073/pnas.0609333103.
14. Jari O, Guillaume B, Roeland K, Pierre L, Peter R, O'Hara R, Gavin L, Peter S, Henry H, Helene W. 2013. Vegan: community ecology R package, version 2.0-10. R Foundation for Statistical Computing, Vienna, Austria.
15. Watkins RR, Bonomo RA. 2013. Increasing prevalence of carbapenem-resistant Enterobacteriaceae and strategies to avert a looming crisis. Expert Rev Anti Infect Ther 11:543-545. http://dx.doi.org/10.1586/eri.13.46.
16. Lewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC, Gobourne A, Ling L, Pamer EG. 2015. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis 212:1656-1665. http://dx.doi.org/10.1093/infdis/jiv256.